News | March 12, 2024
AbCellera and Biogen collaborate on neurological antibody therapy
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Subscribe To Our Newsletter & Stay Updated
